The Latin America, Middle East and Africa Prefilled Syringes Market would witness market growth of 13.9% CAGR during the forecast period (2022-2028).
Growth in the business is anticipated to be boosted by a sharp increase in the production of biological medicines. Due to their greater effectiveness and patient safety with fewer adverse effects, biologic medicines and therapeutic vaccines are quickly replacing the conventional treatment choices. The ongoing availability of biologic pharmaceuticals has increased the need for creative packaging techniques to preserve the efficacy of these exceedingly unstable medications. The parenteral administration of far more than 60% of biologic medications now in development is preferable since any interactions with food or digestive enzymes cause them to degrade. Prefilled syringes are therefore thought to be the best type of storage for such medications.
Needlestick wounds have the potential to be harmful because they can spread deadly illnesses like HIV and hepatitis. Additionally, there is a significant risk of needle stick injuries throughout dose preparation for both patients and medical professionals. Additionally, according to the Centers for Disease Control and Prevention (CDC), employing safety precautions such as prefilled syringes in hospitals could cut down on injuries caused by sharps by 60-88%. This is due to the fact that using prefilled syringes could readily lessen these injuries as their usage avoids the need for numerous dose preparation stages and allows for simple disposal.
In the IDF Africa Region, 24 million persons (20-79) will have diabetes in 2021. By 2030 and 2045, this number is projected to rise to 33 million and 55 million, respectively. In the IDF Africa Region, 52 million persons (20-79) have impaired glucose tolerance (IGT), which puts them at a high risk of getting type 2 diabetes. By 2030 to 2045, such numbers are projected to total 71 million and 117 million, respectively. 54% of the region's 13 million adult diabetics live without a diagnosis, making up the region's total number of diabetic people.
The Brazil market dominated the LAMEA Prefilled Syringes Market by Country in 2021; thereby, achieving a market value of $232.1 million by 2028. The Argentina market is poised to grow at a CAGR of 14.5% during (2022 - 2028). Additionally, The UAE market would experience a CAGR of 13.6% during (2022 - 2028)
Based on Application, the market is segmented into Diabetes, Anaphylaxis, Rheumatoid Arthritis, and Others. Based on Therapeutics, the market is segmented into Large Molecules and Small Molecules. Based on Material, the market is segmented into Glass-based and Plastic-based. Based on Design, the market is segmented into Single-chamber, Dual-chamber, and Customized. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Prefilled Syringes Market is Predict to reach $11.9 Billion by 2028, at a CAGR of 10.5%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Baxter International, Inc., Becton, Dickinson and Company, Gerresheimer AG, Medtronic PLC, Nipro Corporation, Terumo Corporation, Vetter Pharma, West Pharmaceutical Services, Inc.
By Application
By Therapeutics
By Material
By Design
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
